Related Experiment Videos
The efficacy of bromocriptine in benign prostatic hypertrophy. A double-blind study
H Van Poppel1, G Boeckx, K J Westelinck
1Department of Urology, Catholic University, Leuven, Belgium.
British Journal of Urology
|August 1, 1987
Summary
Bromocriptine at 7.5 mg daily showed significant improvements in nocturia and daytime frequency for benign prostatic hypertrophy (BPH) patients. While not impacting uroflowmetry or safety, it offers a potential palliative treatment option for BPH.
Area of Science:
- Urology
- Pharmacology
- Clinical Medicine
Background:
- Benign prostatic hypertrophy (BPH) is a common condition causing lower urinary tract symptoms.
- Palliative treatment options are sought for patients unsuitable for surgery.
Purpose of the Study:
- To evaluate the efficacy and safety of daily bromocriptine (7.5 mg) versus placebo in patients with symptomatic BPH.
- To assess bromocriptine's impact on specific BPH symptoms and objective parameters.
Main Methods:
- A double-blind, placebo-controlled trial involving 32 patients with troublesome BPH symptoms.
- Assessment included uroflowmetry, residual urine measurement, safety parameters, nocturia, daytime frequency, and overall efficacy.
Main Results:
- No statistically significant differences were observed in uroflowmetry, residual urine, or safety parameters between bromocriptine and placebo.
- Bromocriptine demonstrated statistically significant improvements in nocturia, daytime frequency, and overall efficacy compared to placebo.
Conclusions:
- Bromocriptine (7.5 mg daily) may serve as a viable palliative treatment for functional disability associated with BPH.
- It is a potential therapeutic option for patients with BPH who cannot undergo or refuse surgery.